Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Godaddy Inc (GDDY) Price & Performance

Citius Pharmaceuticals IncTrade
Godaddy IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Godaddy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Godaddy Inc trades at $90.75 (market cap $11.49B). The key difference: Godaddy Inc is far larger — about 574.2× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRGDDY
Market Cap
$20.01M$11.49B
Sector
HealthTechnology
52-Week High
$1.82$148.88
52-Week Low
$0.48$75.07
Enterprise Value
$16.23M$14.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

Godaddy Inc

GoDaddy (GDDY) trades at $91.81, up 0.34% today, with a bearish technical signal but strong earnings beats in recent quarters. The company shows robust fundamentals with a 17.83% net income margin and a P/E of 13.48, indicating potential undervaluation. However, recent news highlights multiple securities investigations, creating investor uncertainty. Revenue growth is steady, projected at $5.1B for 2026, while cash flow trends improved in 2024 before a slight dip in 2025.

The stock presents a mixed outlook: analyst consensus is bullish with a $112.13 price target (21 buys, 15 holds, 1 sell), but technical indicators and legal risks weigh on near-term sentiment. Key opportunities include consistent earnings outperformance and solid profitability, while risks involve ongoing legal probes and high debt levels. Investors should balance fundamental strength against headline volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Godaddy Inc

GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.

Read more on GDDY